Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, 18-week, Placebo-controlled, Double-blind, Parallel Group Study Of The Safety And Efficacy Of Pf-05212377 (Sam-760) In Subjects With Mild-to-moderate Alzheimer's Disease With Existing Neuropsychiatric Symptoms On A Stable Daily Dose Of Donepezil

NCT01712074 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01712074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01712074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, 18-week, Placebo-controlled, Double-blind, Parallel Group Study Of The Safety And Efficacy Of Pf-05212377 (Sam-760) In Subjects With Mild-to-moderate Alzheimer's Disease With Existing Neuropsychiatric Symptoms On A Stable Daily Dose Of Donepezil
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2012
Completion date
September 30, 2015
Enrollment
186 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease